The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized Clinical Trial
Abstract
IMPORTANCE: Developing effective vaccines against Ebola virus is a global priority. OBJECTIVE: To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV) and a modified vaccinia Ankara vector vaccine, encoding glycoproteins from Ebola virus, Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein (MVA-BN-Filo). DESIGN, SETTING, AND PARTICIPANTS: Single-center, randomized, placebo-controlled, observer-blind, phase 1 trial performed in Oxford, United Kingdom, enrolling healthy 18- to 50-year-olds from December 2014; 8-month follow-up was completed October 2015. INTERVENTIONS: Participants were randomized into 4 groups, within which they were simultaneously randomized 5:1 to receive study vaccines or placebo. Those receiving active vaccines were primed with Ad26.ZEBOV (5 × 10(10) viral particles) or MVA-BN-Filo (1 × 10(8) median tissue culture infective dose) and boosted with the alternative vaccine 28 or 56 days later. A fifth, open-label group received Ad26.ZEBOV boosted by MVA-BN-Filo 14 days later. MAIN OUTCOMES AND MEASURES: The primary outcomes were safety and tolerability. All adverse events were recorded until 21 days after each immunization; serious adverse events were recorded throughout the trial. Secondary outcomes were humoral and cellular immune responses to immunization, as assessed by enzyme-linked immunosorbent assay and enzyme-linked immunospot performed at baseline and from 7 days after each immunization until 8 months after priming immunizations. RESULTS: Among 87 study participants (median age, 38.5 years; 66.7% female), 72 were randomized into 4 groups of 18, and 15 were included in the open-label group. Four participants did not receive a booster dose; 67 of 75 study vaccine recipients were followed up at 8 months. No vaccine-related serious adverse events occurred. No participant became febrile after MVA-BN-Filo, compared with 3 of 60 participants (5%; 95% CI, 1%-14%) receiving Ad26.ZEBOV in the randomized groups. In the open-label group, 4 of 15 Ad26.ZEBOV recipients (27%; 95% CI, 8%-55%) experienced fever. In the randomized groups, 28 of 29 Ad26.ZEBOV recipients (97%; 95% CI, 82%- 99.9%) and 7 of 30 MVA-BN-Filo recipients (23%; 95% CI, 10%-42%) had detectable Ebola glycoprotein-specific IgG 28 days after primary immunization. All vaccine recipients had specific IgG detectable 21 days postboost and at 8-month follow-up. Within randomized groups, at 7 days postboost, at least 86% of vaccine recipients showed Ebola-specific T-cell responses. CONCLUSIONS AND RELEVANCE: In this phase 1 study of healthy volunteers, immunization with Ad26.ZEBOV or MVA-BN-Filo did not result in any vaccine-related serious adverse events. An immune response was observed after primary immunization with Ad26.ZEBOV; boosting by MVA-BN-Filo resulted in sustained elevation of specific immunity. These vaccines are being further assessed in phase 2 and 3 studies. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02313077.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Henao-Restrepo, A. M., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., Carroll, M. W., Doumbia, M., Draguez, B., Duraffour, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61117-5 · Cited by 793
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Persistence of Ebola Virus in Ocular Fluid during Convalescence
Varkey, J. B., Shantha, J. G., Crozier, I., Kraft, C. S., Lyon, G. M., Mehta, A. K., Kumar, G., Smith, J. R., Kainulainen, M. H., Whitmer, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500306 · Cited by 470
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Liu, J., O’Brien, K. L., Lynch, D. M., Simmons, N. L., La Porte, A., Riggs, A. M., Abbink, P., Coffey, R. T., Grandpre, L. E., Seaman, M. S., et al. (2009) · Nature · doi:10.1038/nature07469 · Cited by 452
Self-citationMolecular Evidence of Sexual Transmission of Ebola Virus
Mate, S. E., Kugelman, J. R., Nyenswah, T. G., Ladner, J. T., Wiley, M. R., Cordier-Lassalle, T., Christie, A., Schroth, G. P., Gross, S. M., Davies-Wayne, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509773 · Cited by 434
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
Agnandji, S. T., Huttner, A., Zinser, M. E., Njuguna, P., Dahlke, C., Fernandes, J. F., Yerly, S., Dayer, J.-A., Kraehling, V., Kasonta, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1502924 · Cited by 412
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
Regules, J. A., Beigel, J. H., Paolino, K. M., Voell, J., Castellano, A. R., Hu, Z., Muñoz, P., Moon, J. E., Ruck, R. C., Bennett, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1414216 · Cited by 387
Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors — Final Report
Deen, G. F., Broutet, N., Xu, W., Knust, B., Sesay, F. R., McDonald, S. L. R., Ervin, E., Marrinan, J. E., Gaillard, P., Habib, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1511410 · Cited by 375
Stanley, D. A., Honko, A. N., Asiedu, C., Trefry, J. C., Lau-Kilby, A. W., Johnson, J. C., Hensley, L., Ammendola, V., Abbate, A., Grazioli, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3702 · Cited by 350
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348
Self-citation
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationLee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Jacob, S. T., Crozier, I., Fischer, W. A., Hewlett, A., Kraft, C. S., Vega, M.-A. D. L., Soka, M. J., Wahl, V., Griffiths, A., Bollinger, L., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0147-3 · Cited by 664
A strategic approach to COVID-19 vaccine R&D
Corey, L., Mascola, J. R., Fauci, A. S., & Collins, F. S. (2020) · Science · doi:10.1126/science.abc5312 · Cited by 502
Metadata
- Authors
- Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., De Rosa, S. C., Frahm, N., Cohen, K. W., Shukarev, G., Orzabal, N., van Duijnhoven, W., Truyers, C., Bachmayer, N., Splinter, D., Samy, N., Pau, M. G., Schuitemaker, H., Luhn, K., Callendret, B., Van Hoof, J., Douoguih, M., Ewer, K., Angus, B., Pollard, A. J., & Snape, M. D.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1610
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2342023283
- Cited by
- 324
- References
- 29
- FWCI
- 31.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2016.4218
- The paper
- Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., De Rosa, S. C., Frahm, N., Cohen, K. W., Shukarev, G., Orzabal, N., van Duijnhoven, W., Truyers, C., Bachmayer, N., Splinter, D., . . . Snape, M. D. (2016). Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2016.4218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.